Migea (Tolfenamic Acid)

Tolfenamic acid works by non‑selectively inhibiting cyclooxygenase‑1 and cyclooxygenase‑2 enzymes, which blocks the synthesis of prostaglandins. Lower prostaglandin levels reduce inflammation, diminish pain signaling, and help control fever.

The specific dose of Migea is determined by the prescribing clinician based on the patient’s condition, age, weight, and renal or hepatic function. Dosage regimens are individualized and should follow the prescriber’s instructions.

The safety of tolfenamic acid in pregnancy and lactation has not been established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and this decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Migea (tolfenamic acid) belongs to the fenamate subclass of NSAIDs, offering analgesic, anti‑inflammatory and antipyretic effects similar to other NSAIDs. Compared with ibuprofen or diclofenac, tolfenamic acid may have a slightly different gastrointestinal risk profile, but overall efficacy for pain and inflammation is comparable.

Migea should be stored at ambient temperature, preferably below 25 °C. Keep the tablets in their original packaging, protect them from moisture and direct sunlight, and ensure they are out of reach of children.

Migea is taken orally, usually with a full glass of water. It may be taken with or without food, but patients with gastrointestinal sensitivity often benefit from taking it with meals to reduce stomach irritation.

Serious risks include severe gastrointestinal bleeding or ulceration, hepatic injury, renal impairment, and rare but life‑threatening skin reactions such as Stevens‑Johnson syndrome. Patients should seek immediate medical attention if they notice unusual bleeding, jaundice, severe rash, or sudden kidney problems.

Migea is contraindicated in individuals with known hypersensitivity to tolfenamic acid or other fenamates, those with active peptic ulcer disease, severe heart failure, or significant renal or hepatic impairment. It should also be avoided in patients taking certain anticoagulants or other NSAIDs without medical supervision.